Jan Pype holds a PhD in Biomedical Sciences from the University of Leuven, Belgium, is FELASA C-certified from the Federation for Laboratory Animal Science Associations, University Ghent, Belgium and followed a certificate in human pharmacology from King’s College, UK. He performed scientific research at the NHLI, ImperialCollege, London, UK before joining UCB Pharma (Belgium), to become group leader of the in vivo Respiratory Pharmacology Group, developing new therapies for asthma, COPD, rhinitis and cough. He then moved to Philip Morris International (PMI) to study mechanism of cigarette smoke-induced diseases and to monitor OECD toxicity tests in a GLP- and AAALAC-certified environment. He was a permanent member of Ethical Committees at UCB Pharma and PMI and is an invited jury member of the IWT (Flemish government agency for Innovation by Science and Technology). He joined Air Liquide Santé International (France) in 2008, to lead the Medical Gases Pharmacology group, investigating the therapeutic potential of medical gases.